Clinical development failure
The company’s value depends on positive trial results for soquelitinib, ciforadenant, and mupadolimab.
- Scope
- Lead program soquelitinib and other pipeline assets
- Materiality
- high
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-modulating drug candidates for cancer, inflammatory diseases, and other immune-mediated disorders. Its lead program, soquelitinib, is being advanced in both T cell lymphoma and atopic dermatitis, while additional candidates such as ciforadenant and mupadolimab remain in clinical development.
6.21
6.21
| % | |
|---|---|
| Soquelitinib | 0% Lead clinical candidate targeting ITK for T cell lymphoma and immune-mediated diseases. |
| Ciforadenant | 0% Clinical-stage oncology candidate designed to modulate adenosine signaling in solid tumors. |
| Mupadolimab | 0% Clinical-stage immune-modulating antibody program being evaluated in cancer settings. |
| Other pipeline programs | 0% Additional preclinical and early clinical assets targeting immune cell function. |
Corvus does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites,...
- Clinical development partnersprimary
CROs, CMOs, and specialist vendors that provide trial execution, manufacturing, and logistics support.
- Clinical trial investigators and sitesprimary
Hospitals and research centers enrolling patients and generating efficacy/safety data for the pipeline.
- Academic and nonprofit collaboratorssecondary
Research institutions that help with translational science, biomarker work, and early development.
- Future oncology and immunology prescribersemerging
Physicians who would prescribe approved therapies for T cell lymphoma or inflammatory disease.
- Future third-party payorsemerging
Insurers and reimbursement bodies that would determine access and adoption after approval.
Corvus is headquartered in South San Francisco, California and operates as a U.S.-based clinical-stage biotech with no...
- •Headquartered in South San Francisco, California
- •No owned manufacturing facilities; relies on third-party CMOs
- •Clinical development is primarily U.S.-based
- •Foreign patent coverage exists for key programs
- •No revenue by country disclosed because the company has no revenue
Corvus is focused on advancing a small number of immune-targeted assets through clinical proof-of-concept, with...
01
Advance soquelitinib in T cell lymphoma and atopic dermatitisshort-term
This is the lead value driver and the most advanced program in the pipeline.
02
Broaden pipeline optionality in oncologymedium-term
Additional indications can diversify clinical risk and extend the platform beyond one asset.
03
Preserve capital through outsourcing and focused developmentshort-term
The company has no commercial revenue and must manage cash carefully until approval or partnering.
04
Secure additional financing or collaborationsmedium-term
Clinical-stage development is capital intensive and the company expects to need more funding.
Corvus is exposed to the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need...
Financing risk
Corvus has no commercial revenue and expects to continue raising capital to fund operations.
- Scope
- Equity dilution and funding availability
- Materiality
- high
Manufacturing and supply chain dependence
The company relies on third parties for drug substance, fill-finish, labeling, and distribution.
- Scope
- Clinical supply continuity and future commercialization
- Materiality
- high
Regulatory approval risk
FDA approval is required before commercialization and can take years with uncertain outcomes.
- Scope
- All product candidates
- Materiality
- high
Patent and competitive risk
Competing therapies or invalidated patents could reduce the commercial opportunity.
- Scope
- Soquelitinib, ciforadenant, mupadolimab
- Materiality
- medium
Clinical trial accruals
Can materially affect R&D expense and accrued liabilities
Fair value of warrant liability
Can distort net loss comparability across periods
Stock-based compensation
Raises operating expense without immediate cash outflow
Going concern and liquidity estimates
Important for assessing dilution and funding risk
Lease accounting
Affects right-of-use assets, lease liabilities, and fixed commitments
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Nuvalent, Inc.
NUVL · Pharmaceutical Preparations
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Coherus Oncology, Inc.
CHRS · Biological Products, (No Diagnostic Substances)
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
IMMUNIC, INC.
IMUX · Pharmaceutical Preparations
: 28/04/2026